Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome.

Management of acute and chronic symptoms of chemotherapy-induced sensory peripheral neuropathy.

Alzheimer’s disease

Has the potential to treat multiple rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses, and Niemann-Pick type C disease (NPC).